Global IgA Nephropathy Treatment Market Growth 2025-2031

The global IgA Nephropathy Treatment market size is predicted to grow from US$ 23 million in 2025 to US$ 69.4 million in 2031;

it is expected to grow at a CAGR of 20.2% from 2025 to 2031.

Currently, there are two main methods for the treatment of IgA nephropathy, one is conservative therapy and the other is immunosuppressive therapy.

Clearances and approval of new drugs, as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups, will have a positive impact on the market growth.

• For instance, US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.

Growing health consciousness coupled with high per capita disposable income is significantly contributing to the market growth.

According to a nationwide study published in the Journal of the American Society of Nephrology, the incidence rate of IgA nephropathy (IgAN) is estimated to be 2-10 per 100,000 individuals a year.

The USA is at high risk for such diseases due to the growing number of chronic diseases and a sedentary lifestyle.

According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults.

As per the report by the Centers for Disease Control and Prevention (CDC) on chronic kidney disease in the United States, in 2021, there are about 37 million people affected by chronic kidney diseases.

ReportPrime, Inc. (LPI) ' newest research report, the “IgA Nephropathy Treatment Industry Forecast” looks at past sales and reviews total world IgA Nephropathy Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected IgA Nephropathy Treatment sales for 2025 through 2031.

With IgA Nephropathy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world IgA Nephropathy Treatment industry.

This Insight Report provides a comprehensive analysis of the global IgA Nephropathy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report also analyzes the strategies of leading global companies with a focus on IgA Nephropathy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global IgA Nephropathy Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for IgA Nephropathy Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity.

With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global IgA Nephropathy Treatment.

• This report presents a comprehensive overview, market shares, and growth opportunities of IgA Nephropathy Treatment market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Corticosteroids
• Immunosuppressant
• ACE and ARB Inhibitors

Segmentation by Application:

• Hospital
• Pharmacy
• Other

This report also splits the market by region:

Americas

• United States
• Canada
• Mexico
• Brazil

APAC

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

Europe

• Germany
• France
• UK
• Italy
• Russia

Middle East & Africa

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Companies coverage:

• AstraZeneca
• Johnson & Johnson Private Limited
• Cipla Inc.
• Hikma Pharmaceuticals PLC
• Zydus Cadila
• LEO Pharma A/S
• Fresenius Kabi AG
• Accord Healthcare
• Abbott
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Lupin
• Alembic Pharmaceuticals Limited
• Apotex Inc
• Eldon Pharmaceutical

Key Questions Addressed in this Report

• What is the 10-year outlook for the global IgA Nephropathy Treatment market?
• What factors are driving IgA Nephropathy Treatment market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do IgA Nephropathy Treatment market opportunities vary by end market size?
• How does IgA Nephropathy Treatment break out by Type, by Application?